Morepen Labs🧬 - Bullish Momentum Building?

The RSI is showing strength, approaching the 67+ zone, hinting at a potential bullish breakout setup. Watch for follow-through in price action to confirm the move. Recent Progress: ✅Receives green light to initiate Bioequivalence (BE) studies for Resmetirom at 60 mg, 80 mg, and 100 mg doses. ✅Aims to tap into the booming Non-Alcoholic Steatohepatitis (NASH) market, projected to reach $16 billion globally by 2032. ✅Positions itself among the first Indian companies preparing for a global launch; also exploring out-licensing opportunities. What are your thoughts on this? Comment below.